Literature DB >> 7981680

Mono- and bi-allelic expression of insulin-like growth factor II gene in human muscle tumors.

P V Pedone1, R Tirabosco, A O Cavazzana, P Ungaro, G Basso, R Luksch, M Carli, C B Bruni, R Frunzio, A Riccio.   

Abstract

Insulin-like growth factor II (IGF-II) is a mitogen for many cell types and an important modulator of muscle growth and differentiation. IGF-II gene is prevalently expressed during prenatal development and its gene activity is regulated by genomic imprinting, in that the allele inherited from the father is active and the allele inherited from the mother is inactive in most normal tissues. IGF-II expression is activated in several types of human neoplasms and an alteration of IGF-II imprinting has been described in Beckwith-Wiedemann syndrome and Wilms' tumor. Here we show that monoallelic expression of IGF-II gene is conserved in normal adult muscle tissue whereas two or more copies of active IGF-II alleles, arising by either relaxation of imprinting or duplication of the active allele, are found in 9 out of 11 (82%) rhabdomyosarcomas retaining heterozygosity at 11p15, regardless of the histological subtype. Since IGF-II has been indicated as an autocrine growth factor for rhabdomyosarcoma cells, these findings strongly suggest that acquisition of a double dosage of active IGF-II gene is an important step for the initiation or progression of rhabdomyosarcoma tumorigenesis. Among different types of muscle tumors, relaxation of imprinting seems to arise prevalently in rhabdomyosarcomas, since we have detected only one case of partial reactivation of the maternal IGF-II allele out of 7 leiomyosarcomas tested.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7981680     DOI: 10.1093/hmg/3.7.1117

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  13 in total

1.  IGF-II dependent autocrine growth in cell lines derived from renal tumours of childhood.

Authors:  W Zumkeller; A Mahmood; R Dellow; P N Schofield
Journal:  Clin Mol Pathol       Date:  1995-12

Review 2.  Genomic imprinting and cancer.

Authors:  J A Joyce; P N Schofield
Journal:  Mol Pathol       Date:  1998-08

3.  Lost miRNA surveillance of Notch, IGFR pathway--road to sarcomagenesis.

Authors:  K Galoian; T Guettouche; B Issac; L Navarro; H T Temple
Journal:  Tumour Biol       Date:  2014-01

4.  Methylation alterations of the MyoD1 upstream region are predictive of subclassification of human rhabdomyosarcomas.

Authors:  B Chen; P Dias; J J Jenkins; V H Savell; D M Parham
Journal:  Am J Pathol       Date:  1998-04       Impact factor: 4.307

Review 5.  Genomic imprinting and chromatin insulation in Beckwith-Wiedemann syndrome.

Authors:  J M Greally
Journal:  Mol Biotechnol       Date:  1999-04       Impact factor: 2.695

6.  Relaxation of insulin-like growth factor 2 imprinting and discordant methylation at KvDMR1 in two first cousins affected by Beckwith-Wiedemann and Klippel-Trenaunay-Weber syndromes.

Authors:  M P Sperandeo; P Ungaro; M Vernucci; P V Pedone; F Cerrato; L Perone; S Casola; M V Cubellis; C B Bruni; G Andria; G Sebastio; A Riccio
Journal:  Am J Hum Genet       Date:  2000-03       Impact factor: 11.025

Review 7.  Parental imprinting regulates insulin-like growth factor signaling: a Rosetta Stone for understanding the biology of pluripotent stem cells, aging and cancerogenesis.

Authors:  M Z Ratajczak; D-M Shin; G Schneider; J Ratajczak; M Kucia
Journal:  Leukemia       Date:  2012-11-08       Impact factor: 11.528

8.  Insulin-like growth factor 2 (IGF2) expression in adrenocortical disease due to PRKAR1A mutations compared to other benign adrenal tumors.

Authors:  Kiran S Nadella; Annabel Berthon; Madson Q Almeida; Isaac Levy; Fabio R Faucz; Constantine A Stratakis
Journal:  Endocrine       Date:  2021-01-09       Impact factor: 3.633

9.  Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma.

Authors:  Lisa E S Crose; Corinne M Linardic
Journal:  Sarcoma       Date:  2011-01-02

10.  Targeting the insulin-like growth factor pathway in rhabdomyosarcomas: rationale and future perspectives.

Authors:  Ana Sofia Martins; David Olmos; Edoardo Missiaglia; Janet Shipley
Journal:  Sarcoma       Date:  2011-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.